Publication Name	World Journal of Transplantation
Manuscript ID	83833
Country	United States

Received	2023-02-10 21:57
Peer-Review Started	2023-02-10 21:59
To Make the First Decision
Return for Revision	2023-03-15 02:58
Revised	2023-04-19 01:27
Second Decision	2023-06-14 02:59
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2023-06-14 09:37
Articles in Press	2023-06-14 09:37
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2023-09-11 10:15
Publish the Manuscript Online	2023-09-15 04:42

ISSN	2220-3230 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Transplantation
Manuscript Type	Minireviews
Article Title	Sodium-glucose cotransporter-2 inhibitor use in kidney transplant recipients
Manuscript Source	Invited Manuscript
All Author List	Pavithra Ramakrishnan, Neetika Garg, Samantha Pabich, Didier A Mandelbrot and Kurtis J Swanson
Funding Agency and Grant Number
Corresponding Author	Kurtis J Swanson, MD, Assistant Professor, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Highland Ave Madison, Madison, WI 53705, United States. kswanson@medicine.wisc.edu
Key Words	Sodium glucose cotransporter-2; Sodium glucose cotransporter-2 inhibitor; Kidney transplantation; Diabetes; Post-transplant diabetes mellitus; New onset diabetes after transplant
Core Tip	Multiple large trials have demonstrated sodium-glucose cotransporter-2 inhibitors (SGLT2i) associated kidney and cardiovascular benefits for chronic kidney disease patients with diabetes. Important considerations are critical to determine safety and efficacy of these medications after kidney transplantation. While evidence is limited, SGLT2i appear to be both safe and effective short-term. More robust research is needed to determine the long-term impacts of their use in kidney transplant recipients. Appropriate patient selection and monitoring are vital to clinical use and future research efforts of SGLT2i in kidney transplantation.
Publish Date	2023-09-15 04:42
Citation	Ramakrishnan P, Garg N, Pabich S, Mandelbrot DA, Swanson KJ. Sodium-glucose cotransporter-2 inhibitor use in kidney transplant recipients. World J Transplant 2023; 13(5): 239-249
URL	https://www.wjgnet.com/2220-3230/full/v13/i5/239.htm
DOI	https://dx.doi.org/10.5500/wjt.v13.i5.239

Full Article (PDF)	WJT-13-239-with-cover.pdf
Full Article (Word)	WJT-13-239.docx
Manuscript File	83833_Auto_Edited-JLW.docx
Answering Reviewers	83833-Answering reviewers.pdf
Audio Core Tip	83833-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	83833-Conflict-of-interest statement.pdf
Copyright License Agreement	83833-Copyright license agreement.pdf
Peer-review Report	83833-Peer-review(s).pdf
Scientific Misconduct Check	83833-Bing-Fan JR-2.png
Scientific Editor Work List	83833-Scientific editor work list.pdf